The company’s TRPV1 antagonist looks doomed.
ApexOnco Front Page
Recent articles
First human data on MK-2010 are imminent.
The project has priority review, but deaths could raise eyebrows.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
